An Open-Label Study to Assess the Effect of Multiple-Dose JNJ26489112 on the Cytochrome P450 Enzymes Using a 3-Probe Substrate Drug Combination in Healthy Subjects.

Trial Profile

An Open-Label Study to Assess the Effect of Multiple-Dose JNJ26489112 on the Cytochrome P450 Enzymes Using a 3-Probe Substrate Drug Combination in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs JNJ 26489112 (Primary) ; Midazolam; Omeprazole; Tolbutamide
  • Indications Anxiety; Diabetes mellitus; Duodenal ulcer; Dyspepsia; Epilepsy; Gastro-oesophageal reflux; Helicobacter infections; Insomnia; Major depressive disorder; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Mar 2012 Actual initiation date changed from Jul 2010 to Jun 2010 as reported by ClinicalTrials.gov.
    • 19 Mar 2012 Additional location (USA) added as reported by ClinicalTrials.gov.
    • 07 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top